1 / 17

Therapeutic Control of the Immune System

Therapeutic Control of the Immune System. June, 2004. Corporate Profile & Mission. Private R&D focused Immunology company with proprietary product candidates addressing large markets with unmet needs

feo
Download Presentation

Therapeutic Control of the Immune System

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Therapeutic Control of the Immune System June, 2004

  2. Corporate Profile & Mission • Private R&D focused Immunology company with proprietary product candidates addressing large markets with unmet needs • Targeting regulatory pathways to restore balance to the immune system in conditions associated with abnormal and harmful immune responses

  3. History Robart’s Research Institute 1996 University Health Network St. Michael’s Hospital U. of Toronto U. of Western Ontario London Health Sciences Centre

  4. Trillium Today • Operating in ~10,000 sq. ft. fully equipped R&D facility in Toronto • Staff: 13 • 4 R&D Programs • Recently closed $13.5M Series A Financing

  5. Corporate Strengths • Strong and innovative science • Proof-of-principle in vivo data • Multiple product opportunities in large markets • World class academic and industry R&D collaborators • Comprehensive patent portfolio • Experienced and committed leadership

  6. Proven Business Model Research R&D Interface Development Scale-up/Formulation PK/Metabolism Toxicology Phase I/Phase IIa Target ID Target Characterization Target Validation Lead ID Lead Optimization Commercial Process Commercial Formulation Phase IIb/Phase III Worldwide registration Lead Compound Development Candidate Marketed Drug

  7. Three Lead Programs - Four Product Opportunities • CD200 CD200Fc: (Primary indications: autoimmunity & transplantation) CD200 MAb: (Primary indications: hematological malignancies) • Pro-inflammatory cytokines Receptor antagonists (Primary indications: Inflammatory disease & cancer) • Fgl2 Fgl2 MAb: (Primary indication: viral hepatitis)

  8. A Solid Research Foundation • Sponsored Research Agreements • Dr. R Gorczynski: CD200 (University Health Network, Toronto) • Dr. G. Levy: Fgl2 (University Health Network, Toronto) • Dr. S. Chemtob: Cytokine R (St. Justine Hospital, Montreal) • Academic Research Collaborators in: • Baltimore • Berlin • Boston • Bristol • Calgary • London (UK) • Maastricht • San Diego • San Francisco • Tübingen

  9. Market Opportunity > $20 Billion • Diabetes • Rheumatoid Arthritis • Psoriasis • Inflammatory Bowel Disease • Multiple Sclerosis • Acute Graft Rejection • Myocarditis • HIV • Viral Hepatitis • Cancer • Nephritis • Allergies • Lupus • Eczema/Dermatitis

  10. Clear Patent Strategy Major market coverage (US, EP, JP, CA, AU)

  11. Management Team • Niclas Stiernholm, Ph.D. Chief Executive Officer (Allelix, YM Biosciences) • Bob Uger, Ph.D. Vice President, R&D (Aventis Pasteur) • Scott Duncan, B.Sc. Director, Patents & Licensing (Allelix) • James Parsons, CA Director, Finance & Admin. (Lorus Therapeutics)

  12. Calvin Stiller, MD (Chair) Chairman, Ontario Research and Development Fund & Canadian Medical Discoveries Fund Brian Underdown, Ph.D. Managing Director, Science and Technology, MDS Capital Corp. Niclas Stiernholm, Ph.D. TTI CEO Robert Hall, M.B.A. Director, Venture Capital Division, Business Development Bank of Canada Julia Levy, Ph.D. Founder and Executive Chairman, Scientific Advisory Board, QLT Inc. Elizabeth Corsi, Pharm D.President & Chief Executive Officer, Eximias Pharmaceutical Corporation Michael Moore, Ph.D. D.Sc. Chief Executive Officer, PIramed Ltd. Gary Levy, M.D. TTI Founding Scientist Representative Board of Directors

  13. Scientific Advisory Board • G. Levy, M.D. (Chair) Director, Multi-Organ Transplant Program at The Toronto Hospital and CIHR Group in Immunology and Transplantation • M. Sayegh, M.D. Director of Research, Immunogenetics and Transplantation, Brigham and Women’s Hospital, Boston • B. Barber, Ph.D. Executive Vice President, University Health Network Global Ventures • V. Kuchroo, DVM, Ph.D. Associate Professor of Neurology, Harvard Medical School, Boston • M. Feldmann, M.D., Ph.D. Professor, Head Kennedy Institute of Rheumatology, Imperial College London, UK

  14. Capitalization • $4.8 M Novartis Inc. contract research (1996-2001) • $250 K Seed financing (1998) • $180 K IRAP (2002) • $13.5 M Series A financing (2004)

  15. Defined Path Forward • Near Term (24 mo): • Secure CD200 partnership(s) • Expand product portfolio; In-house R&D/In-licensing • CD200Fc IND/CTA • Long Term (Yr 3-5): • Phase II/III trials (partner) • Additional IND/CTA filings • Financing • Exit

  16. Corporate Strengths • Strong and innovative science • Proof-of-principle in vivo data • Multiple product opportunities in large markets • World class academic and industry R&D collaborators • Comprehensive patent portfolio • Experienced and committed leadership

  17. Contacts Niclas Stiernholm, PhD Chief Executive Officer Tel: 416-595-0627 x222 niclas@trilliumtherapeutics.com 96 Skyway Avenue Toronto, Ontario, M9W 4Y9 CANADA Bob Uger, PhD Vice President, R&D Tel: 416-595-0627 x260 bob@trilliumtherapeutics.com

More Related